Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer

Invest New Drugs. 1993 May-Aug;11(2-3):203-5. doi: 10.1007/BF00874156.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / secondary
  • Humans
  • Male
  • Neoplasm Staging
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Soft Tissue Neoplasms / secondary
  • Sulfonylurea Compounds / adverse effects
  • Sulfonylurea Compounds / therapeutic use*

Substances

  • Antineoplastic Agents
  • Sulfonylurea Compounds
  • sulofenur